Taken together, consistent with in vitro studies, our results suggested that apatinib inhibited the tumor growth of NSCLC cells by targeting both Nrf2 and VEGFR2/STAT3 signaling in vivo. This evidence concerns the gene NFE2L2 and neoplasm.